Throughout October, CURE highlighted research developments and evolving treatment strategies that continue to shape cancer ...

Regular cancer screenings can detect the disease in its earliest and most treatable stages, yet many people continue to delay ...

A rapid multidisciplinary approach is needed to reduce serum free light chain levels and restore kidney function ...

A new study suggests that many women with early-stage breast cancer may not need radiation after a mastectomy, thanks to ...

1. Huang J. Disitamab vedotin plus tislelizumab as nephron-sparing therapy for high-risk upper tract urothelial carcinoma: The phase II DISTINCT-I trial. Presented at: ESMO 2025 Congress; October ...

A Northwestern team transformed a common chemotherapy drug into a powerful, targeted cancer therapy using spherical nucleic ...

Muscle-invasive bladder cancer management is challenging for cisplatin-ineligible patients due to limited treatment options and high recurrence rates. The Padcev-Keytruda combination therapy ...

Percutaneous cryoablation yields outcomes comparable to robotic surgery for renal cancer, at significantly lower cost, Danish ...

Q3 2025 Earnings Call November 6, 2025 8:00 AM ESTCompany ParticipantsAndrew Barnett - Head of Investor RelationsPascal Soriot - ...

The field of biotechnology has always transformed cutting-edge science into life-changing medicines, but today that transformation is happening at a staggering pace.

Artificial neural networks predicted overall and progression-free survival after chemoradiation in older adults with head and ...

In just the past 8 years since we launched this report, the 5-year survival rate has gone from 18% to nearly 30%,” said Harold Wimmer, President and CEO of the American Lung Association.